ABArjan Bel

Arjan Bel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arjan Bel has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 11 May 2026

    Non-invasive mechanical ventilation reduces cardiorespiratory motion and increases heart-stomach distance for stereotactic arrhythmia radiotherapy: a healthy volunteer study.

    by T Weststrate, I W E M van Dijk, J K Veldman-Landegent, Z van Kesteren, M J Parkes, E M T Dieleman, W F Hoeksema, P G Postema, J Visser, N van Wieringen, et al.

    Stereotactic arrhythmia radiotherapy (STAR) is an emerging non-invasive treatment for patients with therapy-refractory ventricular tachycardia (VT). However, STAR's targeting accuracy is challenged by cardiorespiratory motion, which may necessitate compromises in dose delivery to protect nearby organs at risk (OAR), particularly the stomach. Non-invasive mechanical ventilation at 60 breaths per minute with 15cmH₂O positive end-expiratory pressure (NIMV60P) has been shown to reduce respiratory motion and to potentially increase anatomical separation between thoracic structures. This study aimed to quantify the effect of NIMV60P on cardiorespiratory motion of the left diaphragm and the minimal heart-stomach distance. We retrospectively analyzed MRI data from 22 healthy volunteers who underwent two sessions while free-breathing, breath-holding and undergoing NIMV60P. Diaphragm motion was quantified using coronal cine MRIs. The minimal heart-stomach distance was measured using 3D MRIs during breath-hold inhalation (BH-inhalation), exhalation (BH-exhalation), and NIMV60P. Encompassing volumes of the heart and stomach were generated from BH-inhalation and BH-exhalation scans to evaluate overlap or separation during free-breathing. Lastly, cine frames were deformably registered to assess temporal heart-stomach distance variation. NIMV60P significantly reduced median cranial-caudal diaphragm motion by half from 30 mm (IQR: 16 mm) during free-breathing to 15 mm (IQR: 7 mm, p60P, significantly larger than during BH-inhalation (10.3 mm, p=0.04) and BH-exhalation (4.6 mm, p60P significantly reduces diaphragm motion and increases the distance between heart and stomach in healthy volunteers, supporting its integration with STAR to potentially improve targeting and reduce stomach toxicity, especially for inferior wall VT targets.

  • Open Access

    Benefits of daily online plan adaptation with reduced margins in neoadjuvant chemoradiotherapy for esophageal cancer

    by Leigh A.P. Bruijs, Thomas Weststrate, Karin N. Goudschaal, Irma W.E.M. van Dijk, Jorrit Visser, Joost J.C. Verhoeff, Zdenko van Kesteren, Tezontl S. Rosario, Arjan Bel, Peter S.N. van Rossum

  • Open Access

    Patterns of Hearing Loss in Irradiated Survivors of Head and Neck Rhabdomyosarcoma

    by Franciscus A. Diepstraten, Jan Wiersma, Reineke A. Schoot, Rutger R. G. Knops, Charlotte L. Zuur, Annelot J. M. Meijer, Raquel Dávila Fajardo, Bradley R. Pieters, Brian V. Balgobind, Henrike Westerveld, et al.

    Purpose: The frequency and patterns of HL in a HNRMS survivor cohort were investigated. A dose–effect relationship between the dose to the cochlea and HL was explored. Methods: Dutch survivors treated for HNRMS between 1993 and 2017 with no relapse and at least two years after the end of treatment were eligible for inclusion. The survivors were evaluated for HL with pure-tone audiometry. HL was graded according to the Muenster, Common Terminology Criteria for Adverse Events (CTCAE) v4.03 and International Society for Paediatric Oncology (SIOP) classification. We defined deleterious HL as Muenster ≥ 2b, CTCAE ≥ 2, and SIOP ≥ 2. Mixed-effects logistic regression was used to search for the dose–effect relationship between the irradiation dose to the cochlea and the occurrence of HL. Results: Forty-two HNRMS survivors underwent pure-tone audiometry. The Muenster, CTCAE and SIOP classification showed that 19.0% (n = 8), 14.2% (n = 6) and 11.9% (n = 5) of survivors suffered from HL, respectively. A low-frequency HL pattern with normal hearing or milder hearing loss in the higher frequencies was seen in four survivors. The maximum cochlear irradiation dose was significantly associated with HL (≥Muenster 2b) (p = 0.047). In our series, HL (≥Muenster 2b) was especially observed when the maximum dose to the cochlea exceeded 19 Gy. Conclusion: HL occurred in up to 19% of survivors of HNRMS. More research is needed on HL patterns in HNRMS survivors and on radiotherapy dose–effect relationships.


  • Open Access

    Correction: Quantifying the reduction of respiratory motion by mechanical ventilation with MRI for radiotherapy

    by Z. van Kesteren, J. K. Veldman, M. J. Parkes, M. F. Stevens, P. Balasupramaniam, J. G. van Den Aardweg, G. van Tienhoven, A. Bel, I. W. E. M. van Dijk

  • Open Access

    Quantifying the reduction of respiratory motion by mechanical ventilation with MRI for radiotherapy

    by Z. van Kesteren, J. K. Veldman, M. J. Parkes, M. F. Stevens, P. Balasupramaniam, J. G. van Den Aardweg, G. van Tienhoven, A. Bel, I. W. E. M. van Dijk

    Background: Due to respiratory motion, accurate radiotherapy delivery to thoracic and abdominal tumors is challenging. We aimed to quantify the ability of mechanical ventilation to reduce respiratory motion, by measuring diaphragm motion magnitudes in the same volunteers during free breathing (FB), mechanically regularized breathing (RB) at 22 breaths per minute (brpm), variation in mean diaphragm position across multiple deep inspiration breath-holds (DIBH) and diaphragm drift during single prolonged breath-holds (PBH) in two MRI sessions. Methods: In two sessions, MRIs were acquired from fifteen healthy volunteers who were trained to be mechanically ventilated non-invasively We measured diaphragm motion amplitudes during FB and RB, the inter-quartile range (IQR) of the variation in average diaphragm position from one measurement over five consecutive DIBHs, and diaphragm cranial drift velocities during single PBHs from inhalation (PIBH) and exhalation (PEBH) breath-holds. Results: RB significantly reduced the respiratory motion amplitude by 39%, from median (range) 20.9 (10.6–41.9) mm during FB to 12.8 (6.2–23.8) mm. The median IQR for variation in average diaphragm position over multiple DIBHs was 4.2 (1.0–23.6) mm. During single PIBHs with a median duration of 7.1 (2.0–11.1) minutes, the median diaphragm cranial drift velocity was 3.0 (0.4–6.5) mm/minute. For PEBH, the median duration was 5.8 (1.8–10.2) minutes with 4.4 (1.8–15.1) mm/minute diaphragm drift velocity. Conclusions: Regularized breathing at a frequency of 22 brpm resulted in significantly smaller diaphragm motion amplitudes compared to free breathing. This would enable smaller treatment volumes in radiotherapy. Furthermore, prolonged breath-holding from inhalation and exhalation with median durations of six to seven minutes are feasible. Trial registration: Medical Ethics Committee protocol NL.64693.018.18.


  • Open Access

    Evaluating differences in respiratory motion estimates during radiotherapy: a single planning 4DMRI versus daily 4DMRI

    by Duncan Den Boer, Johannes K. Veldman, Geertjan van Tienhoven, Arjan Bel, Zdenko van Kesteren

    Background: In radiotherapy, respiratory-induced tumor motion is typically measured using a single four-dimensional computed tomography acquisition (4DCT). Irregular breathing leads to inaccurate motion estimates, potentially resulting in undertreatment of the tumor and unnecessary dose to healthy tissue. The aim of the research was to determine if a daily pre-treatment 4DMRI-strategy led to a significantly improved motion estimate compared to single planning 4DMRI (with or without outlier rejection). Methods: 4DMRI data sets from 10 healthy volunteers were acquired. The first acquisition simulated a planning MRI, the respiratory motion estimate (constructed from the respiratory signal, i.e. the 1D navigator) was compared to the respiratory signal in the subsequent scans (simulating 5–29 treatment fractions). The same procedure was performed using the first acquisition of each day as an estimate for the subsequent acquisitions that day (2 per day, 4–20 per volunteer), simulating a daily MRI strategy. This was done for three outlier strategies: no outlier rejection (NoOR); excluding 5% of the respiratory signal whilst minimizing the range (Min95) and excluding the datapoints outside the mean end-inhalation and end-exhalation positions (MeanIE). Results: The planning MRI median motion estimates were 27 mm for NoOR, 18 mm for Min95, and 13 mm for MeanIE. The daily MRI median motion estimates were 29 mm for NoOR, 19 mm for Min95 and 15 mm for MeanIE. The percentage of time outside the motion estimate were for the planning MRI: 2%, 10% and 32% for NoOR, Min95 and MeanIE respectively. These values were reduced with the daily MRI strategy: 0%, 6% and 17%. Applying Min95 accounted for a 30% decrease in motion estimate compared to NoOR. Conclusion: A daily MRI improved the estimation of respiratory motion as compared to a single 4D (planning) MRI significantly. Combining the Min95 technique with a daily 4DMRI resulted in a decrease of inclusion time of 6% with a 30% decrease of motion. Outlier rejection alone on a planning MRI often led to underestimation of the movement and could potentially lead to an underdosage. Trial registration: protocol W15_373#16.007


  • Open Access

    Feasibility of Conebeam CT-based online adaptive radiotherapy for neoadjuvant treatment of rectal cancer

    by Rianne de Jong, Jorrit Visser, Niek van Wieringen, Jan Wiersma, Debby Geijsen, Arjan Bel

    Background: Online adaptive radiotherapy has the potential to reduce toxicity for patients treated for rectal cancer because smaller planning target volumes (PTV) margins around the entire clinical target volume (CTV) are required. The aim of this study is to describe the first clinical experience of a Conebeam CT (CBCT)-based online adaptive workflow for rectal cancer, evaluating timing of different steps in the workflow, plan quality, target coverage and patient compliance. Methods: Twelve consecutive patients eligible for 5 × 5 Gy pre-operative radiotherapy were treated on a ring-based linear accelerator with a multidisciplinary team present at the treatment machine for each fraction. The accelerator is operated using an integrated software platform for both treatment planning and delivery. In all directions for all CTVs a PTV margin of 5 mm was used, except for the cranial/caudal borders of the total CTV where a margin of 8 mm was applied. A reference plan was generated based on a single planning CT. After aligning the patient the online adaptive procedure started with acquisition of a CBCT. The planning CT scan was registered to the CBCT using deformable registration and a synthetic CT scan was generated. With the support of artificial intelligence, structure guided deformation and the synthetic CT scan contours were adapted by the system to match the anatomy on the CBCT. If necessary, these contours were adjusted before a new plan was generated. A second and third CBCT were acquired to validate the new plan with respect to CTV coverage just before and after treatment delivery, respectively. Treatment was delivered using volumetric modulated arc treatment (VMAT). All steps in this process were defined and timed. Results: On average the timeslot needed at the treatment machine was 34 min. The process of acquiring a CBCT, evaluating and adjusting the contours, creating the new plan and verifying the CTV on the CBCT scan took on average 20 min. Including delivery and post treatment verification this was 26 min. Manual adjustments of the target volumes were necessary in 50% of fractions. Plan quality, target coverage and patient compliance were excellent. Conclusions: First clinical experience with CBCT-based online adaptive radiotherapy shows it is feasible for rectal cancer. Trial registration Medical Research Involving Human Subjects Act (WMO) does not apply to this study and was retrospectively approved by the Medical Ethics review Committee of the Academic Medical Center (W21_087 # 21.097; Amsterdam University Medical Centers, Location Academic Medical Center, Amsterdam, The Netherlands).


  • Open Access

    Defining short and prolonged breath-holds

    by Michael Parkes, Jason Cashmore, Stuart Green, Thomas Clutton-Brock, Irma Van Dijk, Zdenko van Kesteren, Geertjan van Tienhoven, Arjan Bel, Joost van Den Aardweg, Markus Stevens


  • Open Access

    Dosimetric benefit of an adaptive treatment by means of plan selection for rectal cancer patients in both short and long course radiation therapy

    by R. de Jong, J. Visser, K. F. Crama, N. van Wieringen, J. Wiersma, E. D. Geijsen, A. Bel

    Background: To compare target coverage and dose to the organs at risk in two approaches to rectal cancer: a clinically implemented adaptive radiotherapy (ART) strategy using plan selection, and a non-adaptive (non-ART) strategy. Methods: The inclusion of the first 20 patients receiving adaptive radiotherapy produced 10 patients with a long treatment schedule (25x2Gy) and 10 patients with a short schedule (5X5Gy). We prepared a library of three plans with different anterior PTV margins to the upper mesorectum, and selected the most appropriate plan on daily Conebeam CT scans (CBCT). We also created a non-adaptive treatment plan with a 20 mm margin. Bowel bag, bladder and target volume were delineated on CBCT. Daily DHVs were calculated based on the dose distribution of the selected and non-adaptive plans. Coverage of the target volume was compared per fraction between the ART and non-ART plans, as was the dose to the bladder and small bowel, assessing the following dose levels: V15Gy, V30Gy, V40Gy, V15Gy and V95% for long treatment schedules, and V15Gy and V95% for short ones. Results: Target volume coverage was maintained from 98.3% (non-ART) to 99.0% (ART)(p = 0.878). In the small bowel, ART appeared to have produced significant reductions in the long treatment schedule at V15Gy, V40Gy, V45Gy and V95% (p < 0.05), but with small absolute differences. The DVH parameters tested for the short treatment schedule did not differ significantly. In the bladder, all DVH parameters in both schedules showed significant reductions (p < 0.05), also with small absolute differences. Conclusions: The adaptive treatment maintained target coverage and reduced dose to the organs at risk. Trial registration: Medical Research Involving Human Subjects Act (WMO) does not apply to this study and was retrospectively approved by the Medical Ethics review Committee of the Academic Medical Center, W19_194 # 19.233.